Members of the RAS superfamily of monomeric GTPases are promising anticancer targets, but previous attempts to therapeutically modulate their activity, which have focused on the development of farnesyltransferase inhibitors, have not proved as successful as hoped. The authors discuss novel approaches targeting prenylation and post-prenylation modifications and the functional regulation of GDP/GTP exchange as exciting alternatives for anticancer therapy.
- Panagiotis A. Konstantinopoulos
- Michalis V. Karamouzis
- Athanasios G. Papavassiliou
